PubMed:32471903 / 1700-1893 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T27","span":{"begin":14,"end":28},"obj":"CHEBI:24261"},{"id":"T28","span":{"begin":14,"end":28},"obj":"CHEBI:24261"},{"id":"T29","span":{"begin":113,"end":116},"obj":"PR:000000134"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease."}

{"project":"Inflammaging","denotations":[{"id":"T17","span":{"begin":0,"end":193},"obj":"Sentence"},{"id":"T17","span":{"begin":0,"end":193},"obj":"Sentence"}],"text":"We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease."}